stoxline Quote Chart Rank Option Currency Glossary
  
NeuroPace, Inc. (NPCE)
8.49  0.27 (3.28%)    12-07 16:00
Open: 8.15
High: 8.5
Volume: 40,632
  
Pre. Close: 8.22
Low: 8.0477
Market Cap: 223(M)
Technical analysis
2023-12-07 4:22:22 PM
Short term     
Mid term     
Targets 6-month :  11.09 1-year :  12.95
Resists First :  9.49 Second :  11.09
Pivot price 8.65
Supports First :  7.65 Second :  6.51
MAs MA(5) :  8.4 MA(20) :  8.54
MA(100) :  6.87 MA(250) :  5.1
MACD MACD :  0.2 Signal :  0.3
%K %D K(14,3) :  35.9 D(3) :  33.4
RSI RSI(14): 55
52-week High :  9.72 Low :  1.22
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ NPCE ] has closed above bottom band by 34.1%. Bollinger Bands are 57.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 8.51 - 8.57 8.57 - 8.61
Low: 7.94 - 8 8 - 8.05
Close: 8.41 - 8.51 8.51 - 8.58
Company Description

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.

Headline News

Thu, 07 Dec 2023
NeuroPace: Making Strides In The Epilepsy Market (NASDAQ:NPCE) - Seeking Alpha

Tue, 05 Dec 2023
NeuroPace and Rapport Therapeutics Collaborate to Advance Revolutionary Epilepsy Treatment - Best Stocks

Tue, 05 Dec 2023
NeuroPace (NASDAQ:NPCE) Price Target Increased to $9.00 by Analysts at Morgan Stanley - Defense World

Sat, 11 Nov 2023
Cantor Fitzgerald Initiates Coverage of NeuroPace (NPCE) with Overweight Recommendation - MSN

Tue, 07 Nov 2023
NeuroPace, Inc. (NASDAQ:NPCE) Q3 2023 Earnings Call Transcript - Yahoo Finance

Thu, 02 Nov 2023
NeuroPace, Inc.'s (NASDAQ:NPCE) top owners are private equity firms with 54% stake, while 21% is held by institutions - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical Devices
Shares Out 26 (M)
Shares Float 9 (M)
Held by Insiders 8.5 (%)
Held by Institutions 87 (%)
Shares Short 151 (K)
Shares Short P.Month 313 (K)
Stock Financials
EPS -1.5
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.62
Profit Margin -63 %
Operating Margin -36.3 %
Return on Assets (ttm) -18.2 %
Return on Equity (ttm) -126.9 %
Qtrly Rev. Growth 47.2 %
Gross Profit (p.s.) 1.23
Sales Per Share 2.29
EBITDA (p.s.) -1.22
Qtrly Earnings Growth 0 %
Operating Cash Flow -24 (M)
Levered Free Cash Flow -15 (M)
Stock Valuations
PE Ratio -5.7
PEG Ratio 0
Price to Book value 13.69
Price to Sales 3.7
Price to Cash Flow -9.22
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android